Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options.
Chicago, IL (PRWEB) May 21, 2013
The prescriptin drug resource center DrugRisks.com is announcing new information on the site for patients taking the blood thinner Pradaxa. A recent study suggests patients taking the drug may be at more risk of death when suffering a head injury than those taking traditional anticoagulants*.
DrugRisks was created to improve the safety of patients taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Health experts have disagreed over whether Pradaxa has higher risks of internal bleeding than traditional blood thinners. The FDA has stated the drug is as safe as warfarin**. However, the Institute for Safe Medication Practices recently warned that Pradaxa bleeding may be nearly 5 times as likely to result in death than bleeding from warfarin or Coumadin***.
The resource center has also added a study from the University of Illinois at Chicago suggesting the data used by the FDA may be flawed, and the risk for Pradaxa bleeding may be higher than expected****.
Now, DrugRisks has learned of a new study published this month in the Journal of Neurosurgery, showing that patients who suffer head trauma while taking Pradaxa are more likely to die of brain hemorrhage than those taking warfarin*.
Due to the number of patients who have filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options. Due to the specialized nature of federal drug injury cases, DrugRisks only recommends lawyers who have already handled Pradaxa lawsuits.
*Journal of Neurosurgery, 5/1/13; thejns.org/doi/pdf/10.3171/2013.3.JNS12503
**FDA 11/2/12; http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
***Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****New England Journal of Medicine, 4/4/13; nejm.org/doi/full/10.1056/NEJMp1302834